- Home
- FATE vs CGTX Comparison
FATE vs CGTX Comparison
Compare FATE & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FATE | CGTX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.8M | 132.4M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FATE | CGTX |
|---|---|---|
| Price | $1.07 | $1.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $3.92 | $3.33 |
| AVG Volume (30 Days) | ★ 1.5M | 974.0K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,137,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $0.22 |
| 52 Week High | $1.94 | $3.83 |
Technical Indicators
Market Signals| Indicator | FATE | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 45.13 |
| Support Level | $0.97 | $1.34 |
| Resistance Level | $1.13 | $1.57 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 63.69 | 31.03 |
Price Performance
Historical ComparisonAbout FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.